WM-115 - Cell Line (ID:50567)
| HMS LINCS ID: | 50567 |
| Name: | WM-115 |
| Alternative Names: | |
| LINCS ID: | LCL-1260 |
| Alternative ID: | CLO_0009613 |
| Parent Cell Line: | |
| Reference Source: | ATCC CRL-1675 |
| Organism: | Homo sapiens |
| Organ: | skin |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | female |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:1909, malignant melanoma |
| Details of Disease: | |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | COSS909784 |
| Verification Reference Profile: | |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | From MGH/CMT as specified by cell provider: Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%. Protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.03% EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 34 to 35°C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 34 to 35°C. Subcultivation ratio: A subcultivation ratio of 1:3 to 1:6 is recommended |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2012-07-31 |
| Most Recent Update: | 2016-04-04 |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20217 | Viability and apoptosis in BRAF(V600E/D) melanoma cell lines monitored by imaging | Microscopy/Imaging |
| 20218 | Phosphorylation state and protein levels measured in BRAF(V600E/D) melanoma cell lines monitored by Reverse Phase Protein Arrays (RPPA) | Reverse Phase Protein Array |
| 20219 | Phosphorylation state and protein levels measured in BRAF(V600E/D) melanoma cell lines monitored by imaging | Microscopy/Imaging |
| 20229 | PLSR model loadings (pMEK and pERK included) from analysis of the covariation of molecular signals with cell viability and apoptosis fraction in BRAF(V600E/D) melanoma cell lines | Analysis |
| 20230 | PLSR model loadings (pMEK and pERK excluded) from analysis of the covariation of molecular signals with cell viability and apoptosis fraction in BRAF(V600E/D) melanoma cell lines | Analysis |
| 20231 | Average variable importance in the projection (VIP) scores from the PLSR models analyzing the covariation of molecular signals with cell viability and apoptosis fraction in BRAF(V600E/D) melanoma cell lines | Analysis |
| 20272 | Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2) | Microscopy/Imaging |
| 20273 | Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of three compounds (viability/apoptosis dataset 2 of 2) | Microscopy/Imaging |
| 20274 | Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 1 of 4) | Microscopy/Imaging |
| 20275 | Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 2 of 4) | Microscopy/Imaging |
| 20276 | Protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with Vemurafenib in combination with chromatin-targeting compounds (immunofluorescence dataset 3 of 4) | Microscopy/Imaging |
| 20277 | Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 4 of 4) | Microscopy/Imaging |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Catalog ID | Provider Batch ID |
|---|---|---|---|
| 50567-1 | Nathan Moerke (Harvard Medical School) | ||
| 50567-2 | Nathan Moerke (Harvard Medical School) | ||
| 50567-3 | Nathan Moerke (Harvard Medical School) |